The partnership will leverage DBV’s skin patch, Viaskin, and Stallergenes’ expertise in respiratory allergies in developing immunotherapy treatments for respiratory allergies.
DBV Technologies chairman and CEO Dr. Pierre-Henri Benhamou said, "The agreement with Stallergenes is very much in line with our strategy to expand our Viaskin proprietary platform beyond food allergies."
DBV will use Viaskin and Stallergenes’ aeroallergens in conducting all preclinical work, up to proof-of-concept studies.
The research on the aeroallergens will be financed by Stallergenes, which will have development and commercialization rights.
Stallergenes CEO Dr. Roberto Gradnik said, "We are very pleased to team up with DBV Technologies, a company that is developing innovative products designed to deliver allergens with epicutaneous immunotherapy."
The companies will enter into license agreements for each aeroallergen thereby defining the opt-in terms for development and commercialization.